{"id":23773,"date":"2025-05-15T07:41:59","date_gmt":"2025-05-15T00:41:59","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23773"},"modified":"2025-05-15T07:41:59","modified_gmt":"2025-05-15T00:41:59","slug":"foresee-pharmaceuticals-announces-a-keynote-oral-presentation-and-participation-at-the-2025-american-thoracic-society-international-conference","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23773","title":{"rendered":"Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference"},"content":{"rendered":"

TAIPEI<\/span><\/span>, May 14, 2025<\/span><\/span> \/PRNewswire\/ — Foresee Pharmaceuticals (TPEx: 6576) (“Foresee”) announced today that it will actively participate in and Toby Maher<\/span>, M.D.<\/b>, will deliver a keynote presentation titled\u00a0“SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma”<\/b>\u00a0at the\u00a0Innovation Theater<\/b>\u00a0on\u00a0May 18, 2025<\/span><\/b>. The session will highlight the design and objectives of the multinational\u00a0syMMPonia Study<\/b>, a pivotal clinical trial evaluating the efficacy of Linvemastat (FP-020), a novel Matrix Metalloproteinase-12 (MMP-12) inhibitor, in patients with uncontrolled asthma.<\/p>\n

Event Details:<\/b>
Speaker<\/b>: Keynote Presentation by Toby Maher<\/span>, M.D., Ph.D.
Title<\/b>:<\/b>\u00a0SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma
When:<\/b> May 18, 2025<\/span> | 1:30 \u2013 2:00 p.m. Pacific Standard Time<\/span>
Where:<\/b>\u00a0American Thoracic Society Innovation Theater 1, San Francisco, CA<\/span><\/p>\n

https:\/\/ats2025<\/span>.d365.events\/directory\/sessions\/c082fddd-5c54-47e7-866e-29b26d7eca3e<\/a><\/b><\/p>\n

Dr. Maher, a renowned expert in the pulmonary field, will present details of the\u00a0syMMPonia Study<\/b>, a\u00a0Phase 2, randomized, double-blinded, placebo-controlled clinical trial<\/b>\u00a0designed to evaluate the efficacy of Linvemastat (FP-020) compared to placebo in patients with\u00a0T2-high, moderate-to-severe asthma<\/b>\u00a0who remain partially controlled despite standard therapy with\u00a0inhaled corticosteroids (ICS)<\/b>\u00a0and\u00a0long-acting beta agonists (LABA)<\/b>.<\/p>\n

The study aims to address unmet needs in asthma management by targeting MMP-12, an enzyme implicated in airway inflammation and remodeling. Attendees will gain insights into the rationale behind targeting MMP-12 in T2-high asthma and the study design, including patient selection and endpoints, and Potential implications for future asthma therapies.<\/p>\n

“Targeting MMP12 represents a paradigm shift, by addressing inflammation and remodeling, Linvemastat (FP-020) could redefine long-term outcomes for patients with poorly controlled asthma. Collaborative efforts to validate these results in the syMMPonia Phase 2 trial are essential to demonstrate statistically significant improvements in FEV1 and reductions in exacerbations alongside biomarker evidence of decreased collagen degradation. These findings could underscore the potential of Linvemastat (FP-020) to modify disease trajectories in high-risk patients,<\/i>” stated Toby Maher<\/span>, M.D., Ph.D., Professor of Clinical Medicine at Keck School of Medicine, of USC<\/span>.<\/b><\/p>\n

\u00a0“<\/b>Today’s progress exemplifies our mission to lead through innovation. syMMPonia trial\u00a0is a testament to our resolve to tackle medicine’s toughest challenges. We are initiating this Phase 2 trial and exploring partnerships in parallel to accelerate patient access worldwide, and we are excited to share our innovation with the clinical community during ATS<\/i>,” stated Dr. Ben Chien<\/span>, Ph.D., Chairman and CEO of Foresee Pharmaceuticals<\/b><\/p>\n

About Linvemastat\u00a0(FP-020)\u00a0and MMP-12<\/b><\/p>\n

Linvemastat (FP-020)\u00a0is a highly potent and selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. Linvemastat\u00a0(FP-020)\u00a0is\u00a0the new-generation MMP-12 inhibitor developed by Foresee following aderamastat (FP-025). It\u00a0exhibits excellent pharmaceutical properties,\u00a0with greater\u00a0potency and similarly high selectivity compared to aderamastat (FP-025). Linvemastat\u00a0(FP-020)\u00a0has shown a favorable efficacy profile in multiple animal models of respiratory diseases and IBD.\u00a0MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. A\u00a0Phase 2 allergen challenge asthma proof-of-concept study in aderamastat (FP-025) has been successfully completed.<\/p>\n

The key role of MMP-12 in disease is supported by single-nucleotide polymorphisms\/genetic evidence related to inflammatory-fibrotic diseases, including asthma and COPD as well as correlative human expression data demonstrating a potential role of MMP-12 in disease severity and treatment responses in asthma, COPD, sarcoidosis, and IBD. MMP-12 is a key immune-fibrotic modulator secreted by macrophages and a key regulator of macrophage, neutrophil, and lung epithelial cell biology and is becoming increasingly recognized as a key marker of inflammatory exacerbations and fibrosis.<\/p>\n

About Foresee Pharmaceuticals Co., Ltd.<\/b><\/p>\n

Foresee is a Taiwan<\/span> and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee’s R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.<\/p>\n

Foresee’s product portfolio includes late and early-stage programs. CAMCEVI 42 mg, or the treatment of advanced prostate cancer, is now approved in the U.S., Canada<\/span>, EU, Taiwan<\/span>, Israel<\/span>, and the UK and was launched in the U.S. in April 2022<\/span>. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted and accepted for review with a PDUFA date of August 29, 2025<\/span>, while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study is ongoing. CAMCEVI 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China<\/span> in collaboration with its partner. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted at severe asthma, COPD, and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is on-going. Building on the compelling biology of ALDH2 and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome\/healthy weight loss and the broader cardiovascular-renal-metabolic space.\u00a0www.foreseepharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TAIPEI<\/span><\/span>, May 14, 2025<\/span><\/span> \/PRNewswire\/ — Foresee Pharmaceuticals (TPEx: 6576) (“Foresee”) announced today that it will actively participate in and Toby Maher<\/span>, M.D.<\/b>, will deliver a keynote presentation titled\u00a0“SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma”<\/b>\u00a0at the\u00a0Innovation Theater<\/b>\u00a0on\u00a0May 18, 2025<\/span><\/b>. The session will highlight the design and objectives of the multinational\u00a0syMMPonia Study<\/b>, a pivotal clinical trial evaluating the efficacy of Linvemastat (FP-020), a novel Matrix Metalloproteinase-12 (MMP-12) inhibitor, in patients with uncontrolled asthma.<\/p>\n

Event Details:<\/b>
Speaker<\/b>: Keynote Presentation by Toby Maher<\/span>, M.D., Ph.D.
Title<\/b>:<\/b>\u00a0SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma
When:<\/b> May 18, 2025<\/span> | 1:30 \u2013 2:00 p.m. Pacific Standard Time<\/span>
Where:<\/b>\u00a0American Thoracic Society Innovation Theater 1, San Francisco, CA<\/span><\/p>\n

https:\/\/ats2025<\/span>.d365.events\/directory\/sessions\/c082fddd-5c54-47e7-866e-29b26d7eca3e<\/a><\/b><\/p>\n

Dr. Maher, a renowned expert in the pulmonary field, will present details of the\u00a0syMMPonia Study<\/b>, a\u00a0Phase 2, randomized, double-blinded, placebo-controlled clinical trial<\/b>\u00a0designed to evaluate the efficacy of Linvemastat (FP-020) compared to placebo in patients with\u00a0T2-high, moderate-to-severe asthma<\/b>\u00a0who remain partially controlled despite standard therapy with\u00a0inhaled corticosteroids (ICS)<\/b>\u00a0and\u00a0long-acting beta agonists (LABA)<\/b>.<\/p>\n

The study aims to address unmet needs in asthma management by targeting MMP-12, an enzyme implicated in airway inflammation and remodeling. Attendees will gain insights into the rationale behind targeting MMP-12 in T2-high asthma and the study design, including patient selection and endpoints, and Potential implications for future asthma therapies.<\/p>\n

“Targeting MMP12 represents a paradigm shift, by addressing inflammation and remodeling, Linvemastat (FP-020) could redefine long-term outcomes for patients with poorly controlled asthma. Collaborative efforts to validate these results in the syMMPonia Phase 2 trial are essential to demonstrate statistically significant improvements in FEV1 and reductions in exacerbations alongside biomarker evidence of decreased collagen degradation. These findings could underscore the potential of Linvemastat (FP-020) to modify disease trajectories in high-risk patients,<\/i>” stated Toby Maher<\/span>, M.D., Ph.D., Professor of Clinical Medicine at Keck School of Medicine, of USC<\/span>.<\/b><\/p>\n

\u00a0“<\/b>Today’s progress exemplifies our mission to lead through innovation. syMMPonia trial\u00a0is a testament to our resolve to tackle medicine’s toughest challenges. We are initiating this Phase 2 trial and exploring partnerships in parallel to accelerate patient access worldwide, and we are excited to share our innovation with the clinical community during ATS<\/i>,” stated Dr. Ben Chien<\/span>, Ph.D., Chairman and CEO of Foresee Pharmaceuticals<\/b><\/p>\n

About Linvemastat\u00a0(FP-020)\u00a0and MMP-12<\/b><\/p>\n

Linvemastat (FP-020)\u00a0is a highly potent and selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. Linvemastat\u00a0(FP-020)\u00a0is\u00a0the new-generation MMP-12 inhibitor developed by Foresee following aderamastat (FP-025). It\u00a0exhibits excellent pharmaceutical properties,\u00a0with greater\u00a0potency and similarly high selectivity compared to aderamastat (FP-025). Linvemastat\u00a0(FP-020)\u00a0has shown a favorable efficacy profile in multiple animal models of respiratory diseases and IBD.\u00a0MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. A\u00a0Phase 2 allergen challenge asthma proof-of-concept study in aderamastat (FP-025) has been successfully completed.<\/p>\n

The key role of MMP-12 in disease is supported by single-nucleotide polymorphisms\/genetic evidence related to inflammatory-fibrotic diseases, including asthma and COPD as well as correlative human expression data demonstrating a potential role of MMP-12 in disease severity and treatment responses in asthma, COPD, sarcoidosis, and IBD. MMP-12 is a key immune-fibrotic modulator secreted by macrophages and a key regulator of macrophage, neutrophil, and lung epithelial cell biology and is becoming increasingly recognized as a key marker of inflammatory exacerbations and fibrosis.<\/p>\n

About Foresee Pharmaceuticals Co., Ltd.<\/b><\/p>\n

Foresee is a Taiwan<\/span> and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee’s R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.<\/p>\n

Foresee’s product portfolio includes late and early-stage programs. CAMCEVI 42 mg, or the treatment of advanced prostate cancer, is now approved in the U.S., Canada<\/span>, EU, Taiwan<\/span>, Israel<\/span>, and the UK and was launched in the U.S. in April 2022<\/span>. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted and accepted for review with a PDUFA date of August 29, 2025<\/span>, while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study is ongoing. CAMCEVI 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China<\/span> in collaboration with its partner. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted at severe asthma, COPD, and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is on-going. Building on the compelling biology of ALDH2 and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome\/healthy weight loss and the broader cardiovascular-renal-metabolic space.\u00a0www.foreseepharma.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23773"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23773\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}